Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- 1 November 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 1 (3), 208-219
- https://doi.org/10.1016/s2213-8587(13)70084-6
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes, Obesity and Metabolism, 2011
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism, 2011
- Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experimentCurrent Medical Research and Opinion, 2011
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humansKidney International, 2011
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and ExerciseDiabetes Care, 2010
- The Obesity Paradox, Weight Loss, and Coronary DiseaseThe American Journal of Medicine, 2009
- Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose‐lowering agentsDiabetic Medicine, 2009
- Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2000